Brazil demands an inside-out strategy
This article was originally published in Clinica
Executive Summary
A couple of recent announcements made by leading health authorities in Brazil may be seen as an invitation to foreign pharmaceutical and medical device companies either to develop and enhance their local businesses, or else to rethink their ability to succeed in this tropical soil.
You may also be interested in...
WORLD VIEW BLOG: New president to Brazil's patent and trademark office: what now?
On 12 December, the president of Brazil's Patent and Trademark Office (INPI), Jorge �vila stepped down, and following a couple of months of market buzz, his replacement was announced as the diplomat, Octavio Brandelli. A highly experienced state official and former Brazilian representative in several international positions, Mr Brandelli is no IPR newcomer. Benny Spiewak, an attorney at Zancaner Costa, Bastos e Spiewak in Sao Paulo, Brazil, takes a look at what his appointment might mean for the Latin American nation that has a foot in both camps in the international IPR debate, and for the relationship between the INPI and the Brazilian regulator ANVISA.